Core Viewpoint - Aimeike, known as "the Moutai for women," is experiencing a significant decline in its business performance, with both revenue and net profit dropping sharply in recent quarters [1][5][10]. Financial Performance - In the first three quarters of 2025, Aimeike reported revenue exceeding 1.86 billion yuan, a year-on-year decrease of over 21%, and a net profit of nearly 1.1 billion yuan, down over 30% [1][5]. - This marks the first time in nearly a decade that Aimeike has experienced a decline in both revenue and net profit over three quarters [2][8]. - The company has seen a continuous decline in performance for four consecutive quarters, with no signs of recovery [2][8]. Product Performance - Aimeike's core products have lost market share, with revenue from its two main products declining in the first half of 2025 [3][11]. - The acquisition of the "童颜针" (Youth Needle) for nearly 1.4 billion yuan has not yet shown positive results in the company's financials [3][12]. - The revenue contribution from Aimeike's main products, including "嗨体" and "濡白天使," has decreased significantly, dropping from 98.57% in 2023 to 95.24% in the first half of 2025 [11][12]. Market Competition - The medical aesthetics industry is facing intensified competition, leading to squeezed profit margins for Aimeike [10][11]. - The market is shifting from expansion to value reconstruction, with a notable increase in competition from new entrants and evolving consumer demands [10][11]. - Aimeike's main products, which include gel and solution injection products, are facing challenges from competitors like 华熙生物 and 圣博玛, which have introduced similar products to the market [11][12]. Historical Context - Aimeike's revenue and net profit had been growing rapidly from 2016 to 2023, with revenue increasing from 141 million yuan to 2.87 billion yuan and net profit from 53 million yuan to 1.86 billion yuan during the same period [5][6]. - The company experienced a slowdown in growth starting in 2024, with revenue and net profit growth rates falling to single digits for the first time since 2016 [6][10].

Industry Overview - In 2025, social consumption and retail enterprises are slowly recovering, with segments like gold jewelry benefiting from high gold prices, while cosmetics and medical aesthetics face intense competition and the rise of domestic brands. Notably, "emotional consumption" remains a key indicator of market vitality [2][8]. Segment Analysis Gold Jewelry - The industry has undergone significant changes, with high gold prices and declining wedding demand affecting traditional brand competitiveness. The rise of emotional consumption and social media marketing has led to the emergence of new brands with differentiated products and consumer insights. Opportunities are seen in high-end Chinese gold and trendy gold segments [3][25]. Retail E-commerce - Offline retailers are transforming from selling "goods" to offering "services and experiences," leveraging their advantages to attract traffic back. Online cross-border e-commerce is expected to enter a demand improvement phase with the easing of interest rates, further enhanced by AI integration [3][19]. Cosmetics - Domestic brands are capitalizing on cultural roots and emotional value to increase market share. Innovations in product safety and emotional value are key, with opportunities in regional and technological narratives, sensitive skin anti-aging, and domestic color cosmetics [3][85]. Medical Aesthetics - High-end consumers show resilience, with a focus on differentiated products from upstream manufacturers and mergers and acquisitions among downstream medical institutions to drive growth [3][5]. Investment Recommendations - Gold Jewelry: Favor brands with differentiated product strength and consumer insights, recommending Chao Hong Ji, Lao Pu Gold, and Chow Tai Fook, with beneficiaries including Chow Sang Sang [3][52]. - Retail E-commerce: Support offline retailers adapting to trends and AI-enabled cross-border e-commerce leaders, recommending Yonghui Supermarket, Ai Ying Shi, Ji Hong Co., and Sai Wei Times [3][82]. - Cosmetics: Highlight domestic brands that meet emotional value and safety innovation, recommending Mao Ge Ping, Pechoin, Shangmei Co., Juzi Biological, Wanmei Biological, and Runben Co. [3][52]. - Medical Aesthetics: Focus on differentiated medical aesthetic product manufacturers and expanding chain medical institutions, recommending Ai Mei Ke and Ke Di-B, with beneficiaries including Mei Li Tian Yuan Medical Health [3][52].

Core Insights - The company reported a decline in revenue and net profit for Q3 2025, with revenue at 566 million and a year-on-year decrease of 21.27% [1] - The company is actively expanding its product pipeline and international market presence, with several new products approved for launch [2] - Despite short-term business pressures, the company maintains a leading gross margin and market share, with projected net profit growth in the coming years [3] Financial Performance - In Q3 2025, the company achieved a net profit of 304 million, down 34.61% year-on-year, and a non-recurring net profit of 255 million, down 42.37% [1] - The sales expense ratio increased by 6.38 percentage points year-on-year, while gross and net profit margins faced slight pressure [1] - R&D expenses as a percentage of revenue rose to 14.30% in Q3 2025, reflecting a commitment to innovation [1] Product Development - The company launched a new product, "Gekela," for treating chin retrusion in May 2025, and received approval for minoxidil solutions in September 2025 [2] - Several products are in the pipeline, including an A-type botulinum toxin for wrinkle treatment and semaglutide injections for weight management [2] - The acquisition of 85% of REGEN Biotech, Inc. enhances the company's product offerings and supports its international expansion strategy [2] Market Outlook - The company anticipates net profits of 1.33 billion, 1.54 billion, and 1.72 billion for 2025-2027, with year-on-year growth rates of -32.2%, +16.3%, and +11.7% respectively [3] - Current stock price corresponds to a PE ratio of 37X for 2025, 31X for 2026, and 28X for 2027, indicating potential for investment [3]

Core Viewpoint - The first-mover advantage of Aimeike is gradually diminishing, leading to a significant decline in revenue and net profit in recent quarters, indicating increased competition and changing market dynamics [3][4]. Group 1: Financial Performance - In Q3 2025, Aimeike reported a revenue of 1.865 billion yuan, a year-on-year decrease of 21.49%, and a net profit of 1.093 billion yuan, down 31.05% [3][5]. - The company's two main business segments, represented by "Ruhbai Angel" and "Haitai," which account for over 95% of revenue, have both seen a revenue decline of around 20% in the first half of the year [5][6]. - Aimeike's gross margin remains high at 93.4% for the first three quarters of this year, maintaining above 93% for the past three years [6]. Group 2: Market Challenges - The medical beauty industry is facing challenges such as insufficient consumer confidence and intensified competition, with new entrants diluting Aimeike's market share [3][5]. - Competitors have introduced similar products at significantly lower prices, such as Huaxi Biological's "Runzhi·Gege," which is priced at 30%-50% of "Haitai," directly impacting Aimeike's customer base [5][6]. - The number of approved products in the market has increased, leading to a more competitive landscape for Aimeike's offerings [6]. Group 3: Strategic Initiatives - Aimeike plans to enhance market competitiveness by focusing on core business, diversifying product lines, and improving service levels and brand influence [9][10]. - The company has begun expanding into skincare and cosmetic raw materials, launching the "Haitai Skincare" series and filing for new cosmetic ingredients [10][11]. - Aimeike has also made strategic acquisitions, such as the purchase of REGEN Biotech for nearly 1.4 billion yuan to strengthen its gel injection product line [6][10].

Core Viewpoint - Aimeike (300896.SZ), a leading player in the medical beauty industry, is experiencing a decline in revenue and net profit, indicating a loss of its competitive edge as new entrants flood the market [1][2]. Financial Performance - In Q3 2025, Aimeike reported revenue of 1.865 billion yuan, a year-on-year decrease of 21.49%, and net profit of 1.093 billion yuan, down 31.05% [1][2]. - The company's gross margin remains high at 93.4%, consistent over the past three years [3][7]. - The company's market capitalization has dropped over 70% from its peak of 172.2 billion yuan in 2021 to 48.4 billion yuan as of October 31, 2025 [7]. Business Challenges - Aimeike's two main business lines, represented by "Haitai" and "Ruhua Tianzi," which account for over 95% of its revenue, are facing significant challenges with a revenue decline of around 20% in the first half of 2025 [2][3]. - Increased competition from new products, such as "Runzhi·Gegge" and "Tongyan Needle," has diluted Aimeike's previous market dominance [2][3]. Strategic Responses - Aimeike plans to enhance market competitiveness by focusing on core business, diversifying product lines, and improving service levels [1][6]. - The company has begun expanding into skincare and cosmetic raw materials, launching the "Haitai Skincare" series and filing for new cosmetic ingredients [6][7]. - Aimeike acquired REGEN Biotech for nearly 1.4 billion yuan to strengthen its gel injection product line, although this acquisition has led to disputes over exclusive agency rights [3][4]. Future Outlook - Aimeike aims to transform into a diversified international giant covering both medical and beauty sectors, with ongoing research in biopharmaceuticals and surgical repair [6][7]. - The contribution of its two main business lines to total revenue has decreased from 98.1% in mid-2024 to 95.3% in mid-2025, indicating a gradual shift towards other business areas [7].

Core Insights - The Biotech Index (970038) closed at 2279.35 points, up 0.77%, with a trading volume of 28.709 billion yuan and a turnover rate of 1.85% [1] - Among the index constituents, 41 stocks rose, with Hualan Vaccine leading at a 17.88% increase, while 8 stocks fell, with Deep Technology leading the decline at 6.38% [1] Index Performance - The Biotech Index saw a net inflow of 140 million yuan from institutional investors, while retail investors contributed a net inflow of 210 million yuan, and there was a net outflow of 350 million yuan from speculative funds [1] Top Constituents - The top ten constituents of the Biotech Index include: - Mindray Medical (sz300760) with a weight of 13.81%, latest price at 215.04, and a decrease of 0.76% [1] - Changchun High-tech (sz000661) with a weight of 5.41%, latest price at 112.26, and a decrease of 2.55% [1] - Kanglong Chemical (sz300759) with a weight of 4.66%, latest price at 33.51, and an increase of 1.12% [1] - Other notable constituents include Muyuans (sz002714) and Aimeike (sz300896) with respective weights of 3.66% and 3.44% [1] Capital Flow Details - Detailed capital flow for key stocks includes: - Mindray Medical saw a net inflow of 26.2 million yuan from institutional investors [2] - Muyuans had a net inflow of 203 million yuan from institutional investors [2] - Hualan Vaccine experienced a net inflow of 74.8 million yuan from institutional investors [2]

爱美客技术发展股份有限公司 规范与关联方资金往来管理制度 爱美客技术发展股份有限公司 规范与关联方资金往来管理制度 第一章 总 则 第一条 为了规范爱美客技术发展股份有限公司(以下简称"公司")与公司 关联方的资金往来,避免公司关联方占用公司资金,保护公司、股东和其他利益相 关人的合法权益,建立防范公司关联方占用公司资金的长效机制,根据《中华人民 共和国公司法》《中华人民共和国证券法》《上市公司治理准则》《深圳证券交易 所创业板股票上市规则》》《上市公司监管指引第 8 号——上市公司资金往来、对 外担保的监管要求》等有关法律、法规和规范性文件及《爱美客技术发展股份有 限公司章程》（以下简称《公司章程》）的规定制定本制度。 第二条 纳入公司合并会计报表范围的子公司与公司关联方之间进行的资金 往来适用本制度。 第三条 本制度所称的关联方与《深圳证券交易所创业板股票上市规则》规 定的关联方具有相同含义。 经营性资金占用,是指公司关联方通过采购、销售等生产经营环节的关联交 易所产生的对公司的资金占用。 爱美客技术发展股份有限公司 规范与关联方资金往来管理制度 非经营性资金占用,是指公司为公司关联方垫付工资、福利、保险 ...

爱美客技术发展股份有限公司 募集资金管理制度 第三条 公司募集资金应当专款专用。公司使用募集资金应当符合国家产业 政策和相关法律法规，践行可持续发展理念，履行社会责任，原则上应当用于主 营业务，有利于增强公司竞争能力和创新能力。 募集资金到位后,公司应及时办理验资手续，聘请符合《证券法》规定的会 计师事务所出具验资报告，并应立即按照招股说明书或可转债募集说明书所承诺 的募集资金使用计划，组织募集资金的使用工作。 第四条 公司董事会应当持续关注募集资金存放、管理和使用情况，有效防 范投资风险，提高募集资金使用效益。 公司的董事、高级管理人员应当勤勉尽责，确保公司募集资金安全，不得操 控公司擅自或变相改变募集资金用途。 第五条 董事会应根据有关法律、行政法规和公司章程的规定，及时披露募 集资金的使用情况。 爱美客技术发展股份有限公司 募集资金管理制度 募集资金限用于公司对外公布的募集资金投向的项目，公司董事会应制定详 第一章 总 则 1 第一条 为规范爱美客技术发展股份有限公司（以下简称公司）募集资金管 理，提高募集资金使用效率，保护股东权益，根据《公司法》《证券法》《深圳证 券交易所创业板股票上市规则》《深圳证 ...

爱美客技术发展股份有限公司 独立董事工作制度 爱美客技术发展股份有限公司 独立董事工作制度 第一章 总 则 第一条 为进一步完善爱美客技术发展股份有限公司（以下简称"公司"） 的法人治理结构，强化对董事会和管理层的约束和监督机制，更好地维护中小股 东的利益，促进公司的规范运作，根据《中华人民共和国公司法》《上市公司独 立董事管理办法》（以下简称"《独立董事管理办法》"）《深圳证券交易所创业 板股票上市规则》（以下简称"《创业板上市规则》"）《深圳证券交易所上市公 司自律监管指引第 2 号——创业板上市公司规范运作》等有关法律、行政法规、 规范性文件和《爱美客技术发展股份有限公司章程》（以下简称《公司章程》）等 相关规定，制定本制度。 第二条 独立董事是指不在公司担任除董事之外的其他职务，并与公司及其 主要股东、实际控制人不存在直接或间接利害关系，或者其他可能影响其进行独 立客观判断的关系的董事。 第三条 独立董事对公司及全体股东负有忠实与勤勉义务，应当按照法律、 行政法规、中国证券监督管理委员会（以下简称"中国证监会"）规定、深圳证 券交易所业务规则和《公司章程》的规定，认真履行职责，在董事会中发挥参与 决策 ...

爱美客技术发展股份有限公司 防范大股东及关联方资金占用专项制度 爱美客技术发展股份有限公司 防范大股东及关联方资金占用专项制度 第一章 总 则 第一条 为了建立防止控股股东及其关联方占用爱美客技术发展股份有限公 司（以下简称"本公司"或"公司"）资金的长效机制，杜绝控股股东及其关联 方占用资金行为的发生，根据《中华人民共和国公司法》《中华人民共和国证券 法》 《上市公司监管指引第 8 号——上市公司资金往来、对外担保的监管要求》 《深圳证券交易所创业板股票上市规则》等法律、法规及规范性文件及《爱美客 技术发展股份有限公司章程》（以下简称《公司章程》）的相关规定，结合公司实 际情况，制定本制度。 第二条 本制度适用于公司及纳入公司合并会计报表范围的子公司与公司控 股股东及其关联方之间的资金往来管理。 第三条 公司董事、高级管理人员对维护公司资金安全负有法定义务。 第四条 占用资金包括经营性占用资金和非经营性占用资金。 经营性占用资金是指控股股东及其关联方通过采购、销售等生产经营环节的 关联交易产生的占用资金。 非经营性占用资金是指为控股股东及其关联方垫付工资、福利、保险、广告 等费用和其他支出，代控股股东及其关 ...